A Phase 3 interventional study of Paliperidone ER in Schizophrenia, sponsored by Janssen Pharmaceutica. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.
Sponsored by Janssen Pharmaceutica (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 4th largest by enrollment, is one of 15 that started in 2007, is one of 41 in phase 3, and was the 80th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,117 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutica, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutica is the lead sponsor of 16 studies on the registry; none are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 5th largest by enrollment of the 176 interventional ones that give a count, is one of 24 that started in 2007, is one of 74 in phase 3, and was the 167th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were previously unsuccessfully treated with other oral antipsychotics.
This is a single arm (one group of participants), multi-center, 6-month study to explore the tolerability, safety and efficacy of flexibly dosed paliperidone ER in participants with schizophrenia previously unsuccessfully treated with an oral antipsychotic medication. Antipsychotic medications are drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders. Unsuccessfully treated means that, despite the participant was treated with an adequate dose of an appropriate oral antipsychotic for an adequate period of time, previous treatment is considered unsuccessful due to lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons. Throughout the study the investigators will adjust the dosage of each participant based on the individual needs. In general, the recommended paliperidone ER dose will be 6 milligram once daily. Participants can be either in- or outpatients and they may take their study drug with or without food. Participants who will complete this 6-month study and would like to continue will be eligible to be enrolled in an extension phase until paliperidone ER is available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
Drug: Paliperidone ER
Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
Drug: Paliperidone ER
Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Percentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 26
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Percentage of participants with greater than or equal to 20 % improvement in PANSS total score is reported here. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Week 26
Change From Baseline in PANSS Total Positive Subscale Score at Week 26
The Positive Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess of or distortion of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Change From Baseline in PANSS Total Negative Subscale Score at Week 26
The Negative Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 26
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Change From Baseline in Personal and Social Performance (PSP) Scale at Week 26
The PSP scale assesses the degree of dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less or equal to 30, functioning so poorly as to require intensive supervision. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Change From Baseline in Sleep Quality at Week 26
Sleep quality was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how well they have slept in the previous 7 days (from 0: "very badly" to 100: "very well"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Change From Baseline in Daytime Drowsiness at Week 26
Daytime Drowsiness was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how often they have felt drowsy within the previous 7 days (from 0: "not at all" to 100:"all the time"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
Number of Participants Within Each Category of Patient Satisfaction Score
Participants were interviewed at baseline and at the end of the trial (Week 26) to assess their satisfaction with the current treatment on a 5-point scale (very good, good, reasonable, moderate or poor). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
Time frame: Baseline and Week 26
| Milestone | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Started | 520 | 597 |
| Completed | 373 | 419 |
| Not completed | 147 | 178 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Adverse event | 40 | 37 |
| Withdrew: Lack of efficacy | 17 | 16 |
| Withdrew: Participant ineligible to continue trial | 1 | 1 |
| Withdrew: Lost to follow-up | 24 | 36 |
| Withdrew: Withdrawal by subject | 36 | 53 |
| Withdrew: Participant non-compliant | 16 | 20 |
| Withdrew: Other | 8 | 11 |
| Withdrew: Adverse event and lack of efficacy (loe) | 3 | 0 |
| Withdrew: Loe and other reason unspecified | 1 | 0 |
| Withdrew: Loe and participant non-compliant | 0 | 1 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| units on a scale | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline | 85.19 ± 24.97 | 65.45 ± 28.48 |
| Week 26 | -26.60 ± 28.24 | -20.52 ± 30.05 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Percentage of participants with greater than or equal to 20 % improvement in PANSS total score is reported here. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| percentage of participants | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Percentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 26 | 72.83 | 71.87 |
The Positive Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess of or distortion of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| units on a scale | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline | 21.04 ± 7.15 | 15.26 ± 7.53 |
| Week 26 | -7.17 ± 7.67 | -5.07 ± 7.88 |
The Negative Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| units on a scale | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline | 22.73 ± 7.86 | 16.90 ± 8.13 |
| Week 26 | -6.93 ± 7.96 | -5.32 ± 8.12 |
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| units on a scale | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline | 4.24 ± 0.83 | 3.29 ± 1.12 |
| Week 26 | -1.12 ± 1.28 | -0.98 ± 1.30 |
The PSP scale assesses the degree of dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less or equal to 30, functioning so poorly as to require intensive supervision. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| units on a scale | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline (n= 506, 583) | 55.07 ± 15.68 | 66.03 ± 15.65 |
| Week 26 (n= 501, 574) | 13.76 ± 17.80 | 11.14 ± 17.53 |
Sleep quality was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how well they have slept in the previous 7 days (from 0: "very badly" to 100: "very well"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| millimeter (mm) | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline (n= 507, 581) | 63.53 ± 27.37 | 67.40 ± 27.13 |
| Week 26 (n= 504, 574) | 11.57 ± 35.70 | 8.19 ± 35.93 |
Daytime Drowsiness was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how often they have felt drowsy within the previous 7 days (from 0: "not at all" to 100:"all the time"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| millimeter (mm) | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Baseline (n= 507, 581 ) | 32.80 ± 27.56 | 34.54 ± 28.61 |
| Week 26 (n= 504, 574) | -9.52 ± 32.29 | -11.54 ± 34.53 |
Participants were interviewed at baseline and at the end of the trial (Week 26) to assess their satisfaction with the current treatment on a 5-point scale (very good, good, reasonable, moderate or poor). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.
| participants | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| Very Good: Baseline (n= 507, 583) | 8 ± 32.74 | 21 ± 34.67 |
| Good: Baseline (n= 507, 583) | 74 | 151 |
| Reasonable: Baseline (n= 507, 583) | 256 | 305 |
| Moderate: Baseline (n= 507, 583) | 158 | 97 |
| Poor: Baseline (n= 507, 583) | 11 | 9 |
| Very Good: Week 26 (n=492, 563) | 120 | 156 |
| Good: Week 26 (n=492, 563) | 173 | 253 |
| Reasonable: Week 26 (n=492, 563) | 112 | 94 |
| Moderate: Week 26 (n=492, 563) | 70 | 50 |
| Poor: Week 26 (n=492, 563) | 17 | 10 |
Collected over 26 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone ER: Lack of Efficacy | — | 35/512 (6.8%) | 208/512 (40.6%) |
| Paliperidone ER: Lack of Tolerability, Compliance or Other | — | 29/587 (4.9%) | 239/587 (40.7%) |
| Event | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| SchizophreniaPsychiatric disorders | 12/512 | 7/587 |
| Psychotic disorderPsychiatric disorders | 7/512 | 3/587 |
| Extrapyramidal disorderNervous system disorders | 0/512 | 3/587 |
| AgitationPsychiatric disorders | 2/512 | 1/587 |
| AggressionPsychiatric disorders | 1/512 | 2/587 |
| VomitingGastrointestinal disorders | 1/512 | 2/587 |
| InvestigationInvestigations | 1/512 | 2/587 |
| HallucinationPsychiatric disorders | 1/512 | 1/587 |
| Suicidal behaviourPsychiatric disorders | 1/512 | 1/587 |
| Abnormal behaviourPsychiatric disorders | 1/512 | 0/587 |
| Event | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other |
|---|---|---|
| InsomniaPsychiatric disorders | 50/512 | 68/587 |
| Extrapyramidal disorderNervous system disorders | 34/512 | 21/587 |
| HeadacheNervous system disorders | 23/512 | 24/587 |
| NauseaGastrointestinal disorders | 17/512 | 23/587 |
| DizzinessNervous system disorders | 16/512 | 22/587 |
| SomnolenceNervous system disorders | 9/512 | 20/587 |
| AkathisiaNervous system disorders | 13/512 | 18/587 |
| VomitingGastrointestinal disorders | 15/512 | 16/587 |
| RestlessnessPsychiatric disorders | 9/512 | 13/587 |
| TremorNervous system disorders | 9/512 | 12/587 |
| Age, Customized(Participants) | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other | Total |
|---|---|---|---|
| Less than (<) 25 years | 92 ± 11.63 | 125 ± 11.90 | 217 |
| Greater than or equal to (>=) 25 to < 35 years | 153 | 191 | 344 |
| >= 35 to < 45 years | 152 | 152 | 304 |
| >= 45 to < 55 years | 83 | 87 | 170 |
| >= 55 to < 65 years | 33 | 34 | 67 |
| >= 65 to < 75 years | 6 | 7 | 13 |
| Greater than 75 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Paliperidone ER: Lack of Efficacy | Paliperidone ER: Lack of Tolerability, Compliance or Other | Total |
|---|---|---|---|
| Female | 192 | 268 | 460 |
| Male | 328 | 329 | 657 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Apr 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 5 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone